# ASPREE Cancer Endpoints Study

> **NCT01968798** · PHASE4 · UNKNOWN · sponsor: **Hennepin Healthcare Research Institute** · enrollment: 14500 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Aspirin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01968798
- **Lead sponsor:** Hennepin Healthcare Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-09
- **Primary completion:** 2019-01
- **Final completion:** 2024-04
- **Target enrollment:** 14500 (ESTIMATED)
- **Last updated:** 2021-04-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01968798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01968798, "ASPREE Cancer Endpoints Study". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01968798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*